Compare CFR & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFR | LNTH |
|---|---|---|
| Founded | 1868 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 6.6B |
| IPO Year | 1994 | 2014 |
| Metric | CFR | LNTH |
|---|---|---|
| Price | $162.57 | $100.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $142.31 | $87.00 |
| AVG Volume (30 Days) | 417.5K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | ★ 5.35 | 2.91 |
| Revenue | ★ $2,235,244,000.00 | $343,374,000.00 |
| Revenue This Year | $9.72 | N/A |
| Revenue Next Year | $4.70 | $14.19 |
| P/E Ratio | ★ $30.26 | $34.60 |
| Revenue Growth | ★ 8.31 | 3.62 |
| 52 Week Low | $119.00 | $49.67 |
| 52 Week High | $170.80 | $111.86 |
| Indicator | CFR | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 45.87 |
| Support Level | $162.32 | $100.51 |
| Resistance Level | $163.81 | $101.43 |
| Average True Range (ATR) | 2.85 | 0.51 |
| MACD | -0.28 | 0.11 |
| Stochastic Oscillator | 55.93 | 43.84 |
Cullen/Frost is a regional US bank with around $54 billion in assets (as of June 2026), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based banking approach that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through targeted branch openings rather than acquisitions. The bank's sweet spot is small to medium-sized Texas-based commercial clients.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.